The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00354627
Recruitment Status : Completed
First Posted : July 20, 2006
Last Update Posted : June 12, 2015
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2012
  Actual Study Completion Date : March 2012